Decision Appropriately Balances Access to Treatment with the Need for More Data on the Clinical Value for Patients
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Friday in reaction to the finalized National Coverage Determination decision for monoclonal antibodies for the treatment of Alzheimer’s from the U.S. Centers for Medicare & Medicaid Services (CMS). The final decision will govern Medicare coverage for the unproven brand name treatment Aduhelm.
“CSRxP commends CMS officials for following through on their proposed coverage determination for Aduhelm, recognizing that more data is needed to determine if there is clinical value for patients,” said CSRxP executive director Lauren Aronson. “CMS’ finalized policy will help ensure more data can be collected while protecting seniors, taxpayers and the U.S. health care system from Big Pharma price-gouging of an unproven treatment. CSRxP looks forward to working with policymakers to ensure future policy decisions continue to balance a medication’s clinical value for patients with its likely cost to consumers and the health care system.”
Read more about Big Pharma’s egregious pricing of Aduhelm HERE.
Learn more about solutions to hold Big Pharma accountable and lower prescription drug prices HERE.
###